COCP - Cocrystal Pharma, Inc.
IEX Last Trade
2.62
0 0%
Share volume: 0
Last Updated: Thu 26 Dec 2024 02:30:01 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
-0.12%
PREVIOUS CLOSE
CHG
CHG%
$2.62
0.00
0.00%
Fundamental analysis
17%
Profitability
0%
Dept financing
2%
Liquidity
50%
Performance
30%
Performance
5 Days
12.00%
1 Month
16.13%
3 Months
48.24%
6 Months
2.86%
1 Year
37.70%
2 Year
27.92%
Key data
Stock price
$2.62
DAY RANGE
$1.70 - $2.62
52 WEEK RANGE
$1.46 - $3.10
52 WEEK CHANGE
$43.18
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Sam Lee
Region: US
Website: cocrystalpharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cocrystalpharma.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cocrystal Pharma, Inc. focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection.
Recent news